Form 4: Spyre Therapeutics CEO Granted Stock Options Worth $8 Million

Cameron Turtle, CEO of Spyre Therapeutics, was granted options to purchase 370,000 shares of common stock on January 15, 2025, according to a recent SEC filing.

Summary

• Cameron Turtle, the CEO of Spyre Therapeutics, was granted stock options on January 15, 2025.
• The options allow Turtle to purchase 370,000 shares of Spyre Therapeutics' common stock at an exercise price of $21.66 per share.
• The options vest in equal monthly installments over four years, contingent upon Turtle's continued employment with the company.
• The options expire on January 15, 2035.
• A Power of Attorney was executed on January 17, 2025, authorizing Ryan Murr, Melanie Neary, Scott Burrows, and Heidy King-Jones to file Forms 3, 4, and 5 on behalf of Cameron Turtle.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders. There are no red flags or negative information in the document.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the stock option grant suggests an expectation of continued employment and contribution from the CEO.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. The size and vesting schedule of the grant are typical for a CEO of a company of Spyre Therapeutics' size and stage.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options to incentivize their executives.
• The vesting schedule of four years is typical, aligning with industry norms for long-term incentive plans.
• The number of shares granted and the exercise price would be benchmarked against peer companies of similar market capitalization and stage of development.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the CEO's interests with theirs.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates